Phase One Development of Rapid COVID-19 Point of Care Test Complete
Pepex Biomedical has effectively concluded first stage development efforts including successfully demonstrating working chemistry and manufacturing functionality of its existing electrochemical biosensor. Atlanta, GA, February 11, 2021 (PR.com) Pepex Biomedical, Inc. (the “Company”), a leading developer of enzymatic biosensor technology, has completed the initial development phase of its forthcoming suite of immunosensor testing products designed to accurately identify COVID-19 antigens and antibodies in under 15 minutes with 95% accuracy.
The scope of the project includes at least four self-administered devices that include two saliva-based sensors; one that will detect the presence of the COVID-19 virus in less than 15 minutes at a greater than 95% accuracy, and a second sensor device with the ability to quantify the viral load. The other two devices use Pepex novel sensor technology to detect antibodies